ReviewCancers2025

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy.

Stefano Molica et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.